Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 272,100 shares, an increase of 11.0% from the November 15th total of 245,200 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average trading volume of 348,600 shares, the days-to-cover ratio is currently 0.8 days.

Coeptis Therapeutics Price Performance

Shares of Coeptis Therapeutics stock opened at $0.18 on Friday. The company has a quick ratio of 0.40, a current ratio of 0.40 and a debt-to-equity ratio of 0.03. The company has a market cap of $7.32 million, a PE ratio of -0.61 and a beta of -0.90. The business has a 50 day moving average of $0.20 and a 200 day moving average of $0.22. Coeptis Therapeutics has a 52 week low of $0.15 and a 52 week high of $1.02.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.